Overview

Dose Finding Study of Albuterol Sulfate in Patients With Intermittent or Persistent Mild Asthma

Status:
Withdrawn
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The drug product albuterol sulfate DPI, TBS-7, is a single dose inhalation product of albuterol sulfate containing 240 ug albuterol sulphate (200 ug of albuterol) and inhalation grade lactose in a new dry powder delivery system called the Trivair deposition system. Three different doses of albuterol sulfate DPI, TBS-7, will be administered in this dose ranging clinical trial: an optimal dose, 80% of the optimal dose and 50% of the optimal dose and will be compared with placebo and an active comparator.
Phase:
Phase 2
Details
Lead Sponsor:
Acerus Pharmaceuticals Corporation
Trimel Biopharma SRL
Treatments:
Albuterol